Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.
Novo Nordisk (NYSE:NVO)’s majority owner has launched a large pan European research program focused on obesity and cardiometabolic diseases.
The initiative aims to speed up research, support startups, and feed potential candidates into Novo Nordisk’s future drug pipeline.
Pfizer is expanding efforts in obesity treatments, including plans for a first in class monthly GLP 1 therapy and broader clinical trials.
Novo Nordisk is a central player in obesity and diabetes care, and this new research push reinforces how important these areas are for the company. By backing early stage science and startups across Europe, its majority owner is seeking to widen the funnel of ideas that could eventually support the NYSE:NVO pipeline. At the same time, Pfizer’s renewed focus on obesity medicines highlights how competitive this field is becoming.
For investors, these parallel moves point to a market where scale, scientific breadth, and clinical execution may become increasingly significant. Novo Nordisk is tying its strategy closely to obesity and cardiometabolic treatments, while Pfizer is working to build a position in monthly GLP 1 therapy. How these efforts progress may influence expectations around market share, pricing, and research priorities in obesity drugs in the future.
Stay updated on the most important news stories for Novo Nordisk by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Novo Nordisk.
NYSE:NVO Earnings & Revenue Growth as at Jun 2026
The CardioMetabolic Bridge program signals that Novo Nordisk is trying to widen its long-term options in obesity and cardiometabolic care while competition intensifies. The Novo Nordisk Foundation is committing DKK 450 million over six years to support academic research and company formation in Europe, with early hubs in London, Italy, and Germany. For investors, the key point is that this sits alongside an already busy internal pipeline that includes oral Wegovy, CagriSema and Etavopivat, and comes as Pfizer, Eli Lilly and others are pushing hard into weight loss and diabetes-related therapies.
Because the foundation is separate from the listed company, this program does not change guidance or address near term earnings pressure that analysts have flagged, including expected year over year earnings declines and questions around longer term growth. Its relevance is more about idea flow and optionality for future drug candidates that could help Novo Nordisk deal with issues such as the forecast earnings trend and the 2031 patent cliff highlighted around ziltivekimab. In a market where Pfizer is planning more than 20 obesity studies and targeting a monthly GLP 1 therapy, breadth of science and access to external projects may become an important part of Novo Nordisk’s business model resilience.
The Risks and Rewards Investors Should Consider
⚠️ The CardioMetabolic Bridge program does not directly resolve analysts’ concerns around forecast earnings declines over the next three years or the large patent expiry expected in 2031.
⚠️ Heightened competition from Pfizer and Eli Lilly in obesity drugs increases execution risk around pricing, trial design, and differentiation for future GLP 1 and cardiometabolic products.
🎁 Foundation backed research and startup support could expand the pool of potential assets that Novo Nordisk can partner on or in license to refresh its obesity and cardiometabolic pipeline.
🎁 The program runs alongside existing positives such as strong recent earnings growth, a GLP 1 franchise that has gained significant traction, and additional candidates like CagriSema and Etavopivat that extend the obesity and hematology stories.
What To Watch Going Forward
From here, keep an eye on how many concrete collaborations and startup deals flow from the CardioMetabolic Bridge network, and whether any projects are explicitly identified as candidates for Novo Nordisk’s pipeline. It is also worth tracking how the company positions its obesity and cardiometabolic offerings against Pfizer’s monthly GLP 1 plans and Eli Lilly’s treatments, particularly around dosing convenience, safety, and payer discussions. Finally, monitor how this broader research push sits alongside other moving parts in the investment case, including forecast earnings trends, flagged risks around dividend coverage and debt, and ongoing commentary about the 2031 patent cliff.
To ensure you’re always in the loop on how the latest news impacts the investment narrative for Novo Nordisk, head to the community page for Novo Nordisk to never miss an update on the top community narratives.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NVO.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com